11 results
This study has been transitioned to CTIS with ID 2023-506873-36-00 check the CTIS register for the current data. The primary objective of this study is: Part 1: To evaluate the efficacy of AL001 compared with placebo as measured by CDR® plus NACC…
The main objective of the study is to investigate MEG-based hippocampal and whole brain neuronal hyperactivity in preclinical DIAD mutation carriers and to find proof-of-concept for the translatability of findings from preclinical AD mouse models to…
Primary objectives:Safety for Dose Selection• To assess the safety and tolerability of PQ912Efficacy • To evaluate the efficacy of PQ912 on working memory and attentionSecondary Objectives:Safety• To assess the safety and tolerability of long-term…
We aim to assess the effects of two approaches of ACP (detailed advance treatment orders versus global goal setting and coping based) on wellbeing of persons with dementia. In addition, we will assess effects on decisional conflict, self-efficacy to…
To investigate whether tear biomarkers can differentiate between patients and controls, and between patient groups.
The current study aims to obtain a better understanding of glymphatic dysfunction in dementia of the Alzheimer*s type and its preclinical stages.The main objective of this study is to improve our understanding of the potential link between…
The aim of this study is to examine whether roflumilast improves cognition in clinical patients with MCI or mild dementia.
Primary Objectives:* Change from baseline to week 48 in cognition according to the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog) compared to placebo.* Changes from baseline to week 48 in ability to perform daily activities according to the…
The purpose of this study is:To investigate how glutamate is processed in the brain using magnetic resonance, a non-invasive technique used to see images of your brain. Glutamate is a chemical that sends signals between nerve cells in the brain.
The primary objective is to determine the safety, tolerability and preliminary efficacy of repeated intrathecal administration of NurOwn® (MSC-NTF: Autologous Mesenchymal Stem Cells [MSC] Secreting Neurotrophic Factors [NTF]) given three times at…
Our primary objective is:i. To assess the quantity and regional distribution of [18F]DPA-714 binding as a marker of microglial activation in patients with FTD compared to controls. Our secondary objectives are: i. To compare the quantity and…